Robeco Institutional Asset Management B.V. Increases Holdings in Exact Sciences Corporation (NASDAQ:EXAS)

Robeco Institutional Asset Management B.V. lifted its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 298.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,629 shares of the medical research company's stock after purchasing an additional 111,343 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.08% of Exact Sciences worth $6,434,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Exact Sciences during the fourth quarter worth about $45,000. AlphaQuest LLC grew its position in shares of Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after acquiring an additional 913 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of Exact Sciences during the 4th quarter worth approximately $66,000. Ostrum Asset Management increased its stake in shares of Exact Sciences by 28.4% during the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock worth $134,000 after purchasing an additional 527 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in shares of Exact Sciences in the 4th quarter worth approximately $149,000. 88.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Barclays reduced their price objective on Exact Sciences from $75.00 to $65.00 and set an "overweight" rating for the company in a report on Tuesday, June 24th. Mizuho began coverage on Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective for the company. Guggenheim restated a "buy" rating and issued a $60.00 price objective on shares of Exact Sciences in a research note on Friday, April 11th. Robert W. Baird increased their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada lifted their target price on shares of Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $70.40.

Exact Sciences Price Performance

Exact Sciences stock traded down $1.05 during midday trading on Thursday, hitting $52.82. 1,668,708 shares of the company's stock were exchanged, compared to its average volume of 2,573,232. The company has a market cap of $9.96 billion, a P/E ratio of -9.59, a PEG ratio of 11.66 and a beta of 0.95. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.38 and a current ratio of 2.73. The stock has a 50-day moving average price of $53.44 and a two-hundred day moving average price of $51.34. Exact Sciences Corporation has a 52-week low of $39.97 and a 52-week high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.16. The company had revenue of $706.79 million during the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative return on equity of 3.75% and a negative net margin of 36.06%. Exact Sciences's revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.60) earnings per share. On average, equities research analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Katherine S. Zanotti sold 3,207 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $53.20, for a total transaction of $170,612.40. Following the sale, the director owned 72,759 shares in the company, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by corporate insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.